Sign in
CompletedNo phase

Somatostatin Receptor Imaging in Acute Myocarditis and Cardiac Sarcoidosis

Key facts

Who runs it
Vastra Gotaland Region
Where
Sweden1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
78 people enrolled
Started
20 Jan 2020
Ended
24 Jun 2024
Type of study
Interventional, 2 groups
Treatments tested
  • 68Ga-DOTA-TOC PET/CT
  • Blood sample
Record updated
27 September 2024

Who can take part

Age
18 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Willingness to participate in the study
  • Provision of written informed consent
  • All patients between the age of 18 and 85 of both genders
  • Newly clinically suspected acute myocarditis or newly clinically suspected cardiac sarcoidosis with or without known extra-cardiac sarcoid

Who cannot take part

  • Other known significant cardiac disease, including previous myocarditis
  • Recent or current somatostatin analogue (octreotide) therapy
  • Known tumour disease, especially (neuro)endocrine tumours
  • Terminal disease(s), advanced psychiatric disease and/or significant dementia
  • Pregnancy or lactation
  • Severe obesity (limited by the scanner)
  • Recent or current immunosuppressive treatment
  • Known relative/absolute contraindications for contrast-enhanced MRI and/or PET/CT imaging
  • Known contraindications for endomyocardial biopsy

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This prospective imaging study investigates the diagnostic ability of Gallium-68 DOTA-TOC (68Ga-DOTA-TOC) positron emission tomography/computed tomography (PET/CT) in the clinical work-up of patients with 1) clinically suspected acute myocarditis (n=30-40) and 2) clinically suspected cardiac sarcoidosis (n=30-40) using clinical diagnostic criteria as well as endomyocardial biopsy as reference. Furthermore, 68Ga-DOTA-TOC PET/CT findings will be compared with results from contrast-enhanced magnetic resonance imaging (MRI) and in case of cardiac sarcoidosis even Fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT, which are both performed as part of the clinical routine work-up.

The 2 groups in the trial

  • Acute myocarditisTreatment being tested

    Included patients with clinically suspected acute myocarditis (n=30-40) will undergo a 68Ga-DOTA-TOC PET/CT and a blood sample will be taken. Furthermore, participants will undergo a contrast-enhanced MRI and endomyocardial biopsy (if clinically indicated) as part of the clinical routine work-up.

    Treatment: 68Ga-DOTA-TOC PET/CT and Blood sample

  • Cardiac sarcoidosisTreatment being tested

    Included patients with clinically suspected cardiac sarcoidosis (n=30-40) will undergo a 68Ga-DOTA-TOC PET/CT and a blood sample will be taken. Furthermore, participants will undergo a contrast-enhanced MRI, 18F-FDG PET/CT and endomyocardial biopsy as part of the clinical routine work-up.

    Treatment: 68Ga-DOTA-TOC PET/CT and Blood sample

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Somatostatin Receptor Imaging in Inflammatory Heart Disease
Record updated
27 September 2024